A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity.
Animals
Antigens, Protozoan
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
/ immunology
Coronavirus M Proteins
/ immunology
Cricetinae
Giardia lamblia
/ immunology
Humans
Immunity
Immunization, Secondary
Immunoglobulin A
/ metabolism
Intestinal Mucosa
/ immunology
Male
Mice
Mice, Inbred BALB C
SARS-CoV-2
/ physiology
Spike Glycoprotein, Coronavirus
/ immunology
Temperature
Vaccine Potency
Vaccines, Virus-Like Particle
COVID-19
VLP (virus-like particle)
mucosal immunity
oral vaccination
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
12
2021
accepted:
07
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
An ideal protective vaccine against SARS-CoV-2 should not only be effective in preventing disease, but also in preventing virus transmission. It should also be well accepted by the population and have a simple logistic chain. To fulfill these criteria, we developed a thermostable, orally administered vaccine that can induce a robust mucosal neutralizing immune response. We used our platform based on retrovirus-derived enveloped virus-like particles (eVLPs) harnessed with variable surface proteins (VSPs) from the intestinal parasite
Identifiants
pubmed: 35281065
doi: 10.3389/fimmu.2022.837443
pmc: PMC8913903
doi:
Substances chimiques
Antigens, Protozoan
0
COVID-19 Vaccines
0
Coronavirus M Proteins
0
Immunoglobulin A
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Virus-Like Particle
0
membrane protein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
837443Informations de copyright
Copyright © 2022 Bellier, Saura, Luján, Molina, Luján and Klatzmann.
Déclaration de conflit d'intérêts
HL and DK are inventors of a patent application claiming orally administered vaccines against coronaviruses that is owned by their public institutions. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Cell Infect Microbiol. 2021 Apr 06;11:655896
pubmed: 33889552
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Mol Ther. 2007 Mar;15(3):457-66
pubmed: 17245356
Lancet Infect Dis. 2021 Jan;21(1):2-3
pubmed: 33069282
Vaccine. 2007 Jul 26;25(30):5467-84
pubmed: 17227687
Expert Rev Vaccines. 2015 Jan;14(1):99-117
pubmed: 25373435
Sci Rep. 2020 Sep 14;10(1):14991
pubmed: 32929138
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Infect Dis. 2020 Mar 5;221(Suppl 1):S113-S122
pubmed: 32134478
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Nat Commun. 2019 Jan 21;10(1):361
pubmed: 30664644
Lancet Infect Dis. 2021 Feb;21(2):e26-e35
pubmed: 33125914
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S391-8
pubmed: 26337116
Drug Discov Today. 2021 Nov;26(11):2619-2636
pubmed: 34332100
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nat Med. 2005 Apr;11(4 Suppl):S45-53
pubmed: 15812489
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Trends Parasitol. 2020 Jan;36(1):7-10
pubmed: 31362858
J Virol. 2017 Oct 13;91(21):
pubmed: 28794025
Expert Rev Vaccines. 2013 Feb;12(2):143-54
pubmed: 23414406
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Expert Rev Vaccines. 2020 Oct;19(10):919-936
pubmed: 32940090
Science. 2020 Nov 13;370(6518):811-818
pubmed: 32958581
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Vaccine. 2009 Sep 25;27(42):5772-80
pubmed: 19656495
Vaccine. 2021 Aug 16;39(35):4988-5001
pubmed: 34304928
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Science. 2020 Nov 27;370(6520):1089-1094
pubmed: 33082295
Clin Vaccine Immunol. 2014 Feb;21(2):174-80
pubmed: 24334684
Sci Transl Med. 2011 Aug 3;3(94):94ra71
pubmed: 21813755
J Biol Chem. 2021 Jan-Jun;296:100111
pubmed: 33229438
Protein Cell. 2015 Jul;6(7):480-503
pubmed: 25944045
Cell. 2020 Oct 1;183(1):169-184.e13
pubmed: 32931734
Nat Rev Immunol. 2021 Feb;21(2):83-100
pubmed: 33353987
Expert Rev Vaccines. 2015 Jul;14(7):913-5
pubmed: 25968245
Nat Commun. 2021 Jan 4;12(1):63
pubmed: 33397909
Science. 2020 Jul 17;369(6501):330-333
pubmed: 32366695
Nat Rev Immunol. 2021 Jul 26;:
pubmed: 34312520
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445
Cell Rep Med. 2020 Oct 20;1(7):100121
pubmed: 32984855
J Clin Virol. 2004 Sep;31(1):69-75
pubmed: 15288617
Nat Commun. 2021 May 25;12(1):3109
pubmed: 34035301